Intravenous Hyaluronidase with Urokinase as Treatment for XXXX .

@entity39 @entity1416 @entity887 @entity35 @entity715
BACKGROUND: Although injection of hyaluronidase into surrounding tissues was proposed to treat arterial hyaluronic acid @entity887 , its application is still rather limited. The authors' goal was to investigate whether intravenous use of hyaluronidase can help resolve hyaluronic acid-induced @entity1416 . METHODS: Inferior epigastric arteries, nourishing inferior abdominal skin of @entity35 , were injected with 0.02 ml of hyaluronic acid to create the animal model. The @entity35 were divided randomly into four groups and given different solutions intravenously: hyaluronidase plus urokinase (group A), hyaluronidase (group B), urokinase (group C), or saline (group D). Progression of tissue @entity39 in all groups was recorded for 1 week. The flap survival rate and mean percentage of surviving flap area were analyzed. RESULTS: The animal model closely imitated actual hyaluronic acid arterial obstruction cases. Flap @entity39 occurrence rates of each group were 10 percent in group A, 70 percent in group B, 80 percent in group C, and 90 percent in group D. The mean surviving flap areas of each group were 92.45 percent (group A), 47.67 percent (group B), 41.41 percent (group C), and 33.19 percent (group D). When hyaluronidase and urokinase were used together, the flap @entity39 rate decreased significantly compared with that of the control group (p < 0.05). Even in cases of @entity39 , group A had a higher average surviving flap area than did the other groups. CONCLUSIONS: Combined use of hyaluronidase and urokinase can help increase the flap survival rate when administered intravenously in intraarterial hyaluronic acid occlusion cases. Both red @entity715 and hyaluronic acid emboli must be dissolved for flap reperfusion. This method shows a promising effect for future application.
